NOVO-VALSARTAN TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
18-03-2011
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
VALSARTAN
Fáanlegur frá:
TEVA CANADA LIMITED
ATC númer:
C09CA03
INN (Alþjóðlegt nafn):
VALSARTAN
Skammtar:
40MG
Lyfjaform:
TABLET
Samsetning:
VALSARTAN 40MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
30/100/500
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0131885003; AHFS:
Leyfisstaða:
CANCELLED PRE MARKET
Leyfisdagur:
2015-10-16
Vara einkenni
PRODUCT MONOGRAPH
PR
NOVO-VALSARTAN
(VALSARTAN)
40 MG, 80 MG, 160 MG AND 320 MG TABLETS
Angiotensin II AT
1
Receptor Blocker
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
Date of Preparation:
October 20, 2010
Control No.: 126534
2
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND
PRECAUTIONS....................................................................................
4
DRUG INTERACTIONS
....................................................................................................
10
DOSAGE AND
ADMINISTRATION................................................................................
10
OVERDOSAGE
..................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 12
STORAGE AND
STABILITY............................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 15
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARMACEUTICAL
INFORMATION............................................................................
17
CLINICAL
TRIALS............................................................................................................
17
DETAILED
PHARMACOLOGY.......................................................................................
24
MICROBIOL
Lestu allt skjalið
